Kenvue Inc. (KVUE)
- Previous Close
19.02 - Open
19.00 - Bid 18.82 x 4000
- Ask 19.12 x 1400
- Day's Range
18.83 - 19.08 - 52 Week Range
17.82 - 27.80 - Volume
15,084,164 - Avg. Volume
16,575,296 - Market Cap (intraday)
36.11B - Beta (5Y Monthly) --
- PE Ratio (TTM)
20.96 - EPS (TTM)
0.90 - Earnings Date --
- Forward Dividend & Yield 0.80 (4.24%)
- Ex-Dividend Date May 7, 2024
- 1y Target Est
22.09
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.
www.kenvue.com22,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: KVUE
Performance Overview: KVUE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KVUE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KVUE
Valuation Measures
Market Cap
36.11B
Enterprise Value
43.16B
Trailing P/E
20.96
Forward P/E
16.39
PEG Ratio (5yr expected)
2.08
Price/Sales (ttm)
2.26
Price/Book (mrq)
3.22
Enterprise Value/Revenue
2.79
Enterprise Value/EBITDA
13.59
Financial Highlights
Profitability and Income Statement
Profit Margin
10.77%
Return on Assets (ttm)
6.67%
Return on Equity (ttm)
10.67%
Revenue (ttm)
15.44B
Net Income Avi to Common (ttm)
1.66B
Diluted EPS (ttm)
0.90
Balance Sheet and Cash Flow
Total Cash (mrq)
1.38B
Total Debt/Equity (mrq)
75.17%
Levered Free Cash Flow (ttm)
2.8B
Research Analysis: KVUE
Company Insights: KVUE
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: KVUE
Analyst Report: Kenvue Inc.
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
RatingPrice TargetAnalyst Report: Kenvue Inc
Kenvue Technologies Inc., formerly part of Johnson & Johnson, is a pure-play consumer health company. The company has three segments: Self Care, Skin Health & Beauty, and Essential Health. Major brands include Tylenol, Nicorette, Zyrtec, Neutrogena, Aveeno, Listerine, and Band-Aid. The company has 22,200 employees. KVUE shares are a component of the S&P 500.
RatingPrice TargetMarket Digest: ADSK, KO, PSA, SILK, KVUE
Rallying Market Ignores Warning Signs: Our Monthly Survey of the Economy, Interest Rates, and Stocks
Analyst Report: Kenvue Inc.
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
RatingPrice Target